United States cost-effectiveness study of two dry eye ophthalmic lubricants

Ophthalmic Epidemiology

Volumn 16, Issue 1, 2009, Pages 22-30

  Wlodarczyk, John ^a   Fairchild, Carol ^b  

^a John Wlodarczyk Consulting Services   (Australia)

^b ALCON RESEARCH LTD   (United States)

Author keywords

Cost effectiveness; Dry eye; QALY; Systane

Indexed keywords

CYCLOSPORIN A; EYE DROPS; REFRESH TEARS; SYSTANE; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG ANTAGONISM; DRUG COST; DRUG EFFICACY; DRUG POTENTIATION; DRY EYE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; UNITED STATES;

COST-BENEFIT ANALYSIS; DRY EYE SYNDROMES; HUMANS; LUBRICANTS; MODELS, ECONOMIC; OPHTHALMIC SOLUTIONS; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; TREATMENT OUTCOME; UNITED STATES;

EID: 61649112229     PISSN: 09286586     EISSN: 17445086     Source Type: Journal    
DOI: 10.1080/09286580802521309     Document Type: Article

References (31)

1. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
2. Bandeen-Roche K, Munoz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997;38:2469-2475.
3. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
4. Schein OD, Munoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
5. Yazdani C, McLaughlin T, Smeeding JE, et al. Prevalence of treated dry eye disease in a managed care population. Clin Ther. 2001;23:1672-1682.
6. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: A conceptual framework and preliminary assessment. Cornea 2004;23:751-761.
7. Dalzell MD. Dry Eye: Prevalence, utilisation, and economic implications. P&T Digest 2003; 12:9-13.
8. Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221-232.
9. Chia EM, Mitchell P, Rochtchina E, et al. Prevalence and associations of dry eye syndrome in an older population: The Blue Mountains Eye Study. Clin ExperOphthalmol. 2003;31:229-232.
10. Simmons PA, Vehige JG, Carlisle C, et al. Comparison of dry eye signs in self described mild and moderate patients. Association for Research in Vision and Ophthalmology Meeting Abstracts 2003;44(5):2448.
11. Schein OD, Tirlsch JM, Munoz B, et al. Relation between signs and symptoms of dry eye in the elderly - A population based perspective. Ophthalmology 1997;104:1395-1401.
12. Perry HD, Donnenfeld ED. Medications for dry eye syndrome: A drug-therapy review. P&T Digest 2003;12:26-32.
13. Swanson M. Compliance with and typical usage of artificial tears in dry eye conditions. J Am Optom Assoc. 1998;69:649-655.
14. Balaram M, Schaumberg DA, Dana MR. Efficacy and tolerability outcomes after punctal occlusion with silicone plugs in dry eye syndrome. Am J Ophthalmol. 2001;131:30-36.
15. Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health 2005;8:168-174.
16. Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003;110:1412-1419.
17. Mertzanis P, Abetz L, Rajagopalan K, et al. The relative burden of dry eye in patients' lives: Comparisons to a U.S. normative sample. Invest Ophthalmol Vis Sci. 2005;46:46-50.
18. Miljanovic B, Dana R, Sullivan DA, et al. Impact of dry eye syndrome on vision-related quality of life. Am J Ophthalmol. 2007;143:409-415.
19. AC Nielsen Point of Sale Report: First Quarter. 2007.
20. DEWS Report of the International Dry Eye Workshop (DEWS). Ocular Surface 2007;5:65-199.
21. Christensen MT, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res. 2004;28:55-62.
22. Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32:21-26.
23. Noecker RJ. Comparison of initial treatment response to two enhanced-viscosity artificial tears. Eye Contact Lens. 2006;32:148-152.
24. Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489-1496.
25. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-188.
26. Physicians' Fee and Coding Guide, Vol 2. Duluth GA:; MAG Mutual Healthcare Solutions Inc., 2007.
27. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther. 2000;17:84-93.
28. Clegg JP, Guest JF, Lehman A, et al. The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden, and the United Kingdom among patients managed by ophthalmologists. Ophthalmic Epidemiol. 2006;13:263-274.
29. Chiang TH, Walt JG, McMahon Jr. JP, et al. Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care. Can J Clin Pharmacol. 2007;14:e240-5.
30. Brown GC, Brown MM, Sharma S, et al. The burden of age-related macular degeneration: A value-based medicine analysis. Trans Am Ophthalmol Soc. 2005;103:173-84; discussion 184-186.
31. Kymes SM, Lee BS. Preference-based quality of life measures in people with visual impairment. Optom Vis Sci. 2007;84:809-816.